Enroll first patient in Phase 3 confirmatory trial of RP1
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 16 May 2024
- Due
- 31 Dec 2024
- Delivered
- August 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Enrollment of first patients in Phase 3 confirmatory trial of RP1 in advanced melanoma expected in 2H 2024”
What we found
Evidence strength A What the grades mean
The company announced the dosing of the first patient in the IGNYTE-3 Phase 3 confirmatory trial in August 2024, which is within the second half of 2024.
-
A Replimune Group, Inc. 10-Q filed 2025-08-07
“In August 2024, we announced the dosing of the first patient in the IGNYTE-3 trial” ✓ confirmed on the page
Market reaction: the shares moved -9.8% against the S&P 500 over the three sessions around the disclosure (6 Aug 2025 to 11 Aug 2025). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift -92 days
- 2 versions
-
Version 1 · original · stated 16 May 2024
Deadline 31 Dec 2024 (“2H 2024”) · wording expected
-
Version 2 · stated 8 Aug 2024
Deadline 30 Sep 2024 (“Q3 2024”) · target 1 patient · wording expected
“Enrollment of first patient in Phase 3 confirmatory trial of RP1 in advanced melanoma expected in Q3 2024”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Enroll
- Deliverable
- Phase 3 confirmatory trial enrollment
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Replimune Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-REPL-002732 · Corrections policy